Condeco Launches New Marketing Campaign to Address the Greatest Cultural Shift in Business of the 21st Century
12.4.2022 15:30:00 EEST | Business Wire | Press release
Condeco, a global leader in workspace scheduling software, is today announcing the launch of its new marketing campaign that is uniquely designed to address the immediate need for businesses to redefine the workplace and respond to the evolving expectations of their employees.
Condeco’s campaign will debut with a new film short that showcases the needs of the modern workplace and contextualizes the new wave of business culture that is turning the traditional office environment on its head. Positioned as a satirical comedy, the film short highlights the growing generational divide that has emerged out of the pandemic, and light-heartedly cements the importance of having an employer that understands and embraces employee needs.
In addition to the launch of this new film, Condeco’s new marketing campaign includes a new consumer report that supports the importance of fostering a workplace that respects the desires of its employees, with hybrid work opportunities at its core. As full-time remote work becomes a pandemic pastime, this report’s findings underscore the need for business leaders to prioritize employee happiness, mental health, and digital technology as they adopt hybrid work models.
“It’s no secret that there has been a seismic shift in how we work” said Lynda Lowe, CMO at Condeco. “Work is now an outcome that is no longer defined by a single physical location and there is a growing tension point between business leaders who are trying to force a return to the office and their employees who want to be able to work flexibly. But this does not mean that leaders should discount the value of the office altogether. Instead, leaders must understand the value of the office has shifted to providing a safe space for employee collaboration. The past two years have taught us that empowering employees with time and space to do this at their choosing is key to supporting their mental health and well-being, as well as driving enhanced business culture and social interaction.”
Condeco’s new marketing campaign follows the brand’s repositioning in 2021, which recognized the immediate need for employers to provide their employees with the flexibility to work from anywhere. Delivering on its mission to help businesses redefine their workplace, Condeco acquired ProxyClick in January 2022 to expand Condeco’s workspace solutions for the enterprise, enabling the company to drive an end-to-end employee and guest experience with the connected office – and ultimately, help businesses prepare for the future at work.
Condeco’s new film will air across connected TV and social channels starting on Tuesday, April 12, 2022. Media planned and bought by Hubble, part of What’s Possible Group. The film was produced by Arts & Sciences and directed by Casey Storm, who is known for his work with brands including Paypal, Apple, Hulu, Expedia, and more.
To view the full broadcast, please see here: https://youtu.be/HunkSOvLJ4M. To learn more about Condeco’s new report on hybrid work, please see here.
About Condeco
Condeco is the global leader in enterprise level workspace solutions. Our software is designed to equip everyone with the tools they need for a seamless end to end experience in today’s office. By giving people control over flexible work, we deliver the certainty people need, enable the collaboration teams crave, and facilitate the insights on capacity that employers demand. From visitor management to workspace booking to office optimization, we are trusted by over 2000 of the world’s largest companies to realize their future at work.
About Arts & Sciences
Arts & Sciences was started over a decade ago as a boutique production company that specializes in producing award-winning advertising content, music videos, fine art projects, original documentaries, and feature films. Located in Los Angeles, NYC, and London, Arts & Sciences represents a diverse group of top directors and creators and has been named a Creativity A-List Production Company five times. Every major advertising award show has recognized its work, including Cannes Lions, Clio, AICP, D&AD, The One Show, and the Andys. Their original content work has been featured in the New Frontiers showcase at the Sundance Film Festival, The New Yorker, Nowness, and Purple Magazine. Arts & Sciences has produced work for every major global brand, such as Google, Apple, Facebook, Nike, AT&T, Samsung, Volkswagen, Ford, Toyota, American Express, MLB, the NFL, and more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005251/en/
Contact information
Sydney Huffman
sydney.huffman@fleishman.com
(203) 247-9784
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
